Kadmon Holdings, Inc.:
Announced pos. primary analysis results (May 2020) in pivotal trial of ROCK inhibitor-KD025 (Belumosudil) in cGVHD pts receiving 2+ prior therapy lines; ORRs of 73% and 74% in 200mg QD and 200mg BID arms, respectively. Belumosudil is being reviewed under Real-Time Oncology Review (RTOR) Pilot Program by the FDA; NDA submission exp Q4 2020. Enrolling pts in Ph 2 trial (sys. sclerosis).
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Middle Atlantic
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Fibrosis, Immunotherapy, Oncology
Industry
Biotechnology, Pharmaceuticals
Listing
Public, USA
Market Cap
500MM - 1B
Website:
Profiles:
Address:
450 East 29th Street
New York, NY 10016
United States
New York, NY 10016
United States
Company Participants at Solebury Trout CEO & Investor Ski Conference 2020
- Ellen Cavaleri, Director, Investor Relations
- Harlan W. Waksal, MD, President and CEO
- Steve Meehan, CFO
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Lead Programs
KD025
| Indication | Phase |
|---|---|
| Chronic Graft-Versus-Host Disease | 2 |
| Systemic Sclerosis | 2 |
| Idiopathic Pulmonary Fibrosis | 2 |
KD034
| Indication | Phase |
|---|---|
| Wilson’s Disease | 3 |
Top 10 Holders of Kadmon Holdings Inc Warrant 2017-28.09.22 On Kadmon Hldngs
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| The Vanguard Group, Inc. | 0.00 | 0 | 0.00 | Funds | 2020-05-31 |
Top 10 Holders of Kadmon Holdings, Inc.
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | 12.13 | 15,711,334 | 73.84 | 13F | 2020-03-31 |
| Consonance Capital Management LP | 12.06 | 15,608,948 | 73.36 | 13F | 2020-03-31 |
| Vivo Capital LLC | 9.68 | 12,539,515 | 58.94 | 13F | 2020-03-31 |
| Third Point LLC | 7.27 | 9,407,745 | 44.22 | 13F | 2020-03-31 |
| The Vanguard Group, Inc. | 6.27 | 8,114,440 | 38.14 | Funds | 2020-05-31 |
| Vanguard Group, Inc. (Subfiler) | 6.04 | 7,826,873 | 36.79 | 13F | 2020-03-31 |
| Boxer Capital LLC | 4.79 | 6,205,882 | 29.17 | 13F | 2020-03-31 |
| Citadel LP | 4.55 | 5,891,517 | 27.69 | 13F | 2020-03-31 |
| BlackRock Fund Advisors | 4.29 | 5,554,287 | 26.11 | 13F | 2020-03-31 |
| T. Rowe Price Associates, Inc. (Investment Management) | 4.27 | 5,527,706 | 25.98 | 13F | 2020-03-31 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.